Capricor Therapeutics reports Q3 EPS (38c), consensus (36c)
The Fly

Capricor Therapeutics reports Q3 EPS (38c), consensus (36c)

Reports Q3 revenue $2.3M, consensus $3.57M. Cash, cash equivalents and marketable securities totaled approximately $85.0M as of September 30, 2024 compared to $39.5M as of December 31, 2023. The company believes that based on the current operating plan and financial resources, its available cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements into 2027.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App